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PATIENT VERSUS PHYSICIAN PERCEPTIONS OF PROGNOSIS AND END-OF-LIFE 
OUTCOMES IN ACUTE LEUKEMIA. 
Sophia Shimer and Kerin Adelson.  Section of Medical Oncology, Department of Internal 
Medicine, Yale School of Medicine, New Haven, CT.  
 
Background: Acute leukemia poses unique challenges for prognostication.  In many 
cases, cure is possible but unlikely and treatment is risky.  Little is known about how 
patients perceive their prognosis.  The purpose of this study was to assess prognostic 
understanding and end-of-life outcomes in patients with acute leukemia. 
 
Methods: In this observational study, we surveyed patients admitted with acute 
leukemia and their treating hematologists.  We elicited patient preferences for 
prognostic information and asked whether goals of care discussions had occurred.  We 
then compared patient vs physician perceptions of treatment goals, chance of cure, 
expected survival, and chance that treatment would lessen suffering.  Patient-physician 
concordance was assessed with kappa statistics.  After a minimum follow-up of 1 year, 
we compared perceptions of prognosis to actual survival outcomes.  Finally, we 
measured healthcare utilization at the end of life.  
 
Results: We enrolled 76.6% (105/137) of eligible patients.  We restricted our analysis to 
the 90 patient-physician dyads in which both parties completed a survey.  Although 
83.5% of patients wanted to be told their prognosis, only 56.8% recalled their physician 
disclosing treatment response rates.  Most patients (82.2%) and physicians (78.9%) 
shared a goal of cure.  However, they differed significantly in their perceptions of the 
chance of cure.  Both non-relapsed and relapsed patients were more likely than their 
physicians to report a > 80% chance of cure (57.9% vs 5.2% for non-relapsed, p < 0.001; 
38.7% vs 0.0% for relapsed, p < 0.001).  Among those willing to estimate survival time, 
75.7% of patients vs 28.4% of physicians estimated > 5 years (p < 0.001).  Patients were 
also more likely to report a > 80% chance that treatment would lessen suffering (50.6% 
vs 21.6%, p < 0.001).  Patient-physician concordance was poor for both chance of cure (κ 
= 0.05) and chance of lessening suffering (κ = 0.02).  When prognostic perceptions were 
compared to actual survival outcomes, 54.1% of patients and 33.8% of physicians 
overestimated survival.  The analysis of healthcare utilization at the end of life revealed 
high rates of in-hospital death (50.0%); hospitalization (93.8%) and ICU admission 
(54.2%) within 30 days of death; and hospice enrollment within 7 days of death (37.5%).  
 
Conclusions: Most patients overestimate their prognosis compared to their 
hematologist’s assessment and actual survival outcomes.  This finding is significant 
because, while optimism can help with coping, there is also a risk of unrealistic 
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Most patients with cancer want to know their prognosis and participate actively in 
decision-making regarding their care.1-3  The American Society of Clinical Oncology has 
issued consensus guidelines recommending that oncologists broach discussions about 
prognosis and goals of care earlier in the course of illness, not just at the end of life.4,5  
Despite the growing call from both patients and oncologists for improved 
communication about prognosis, many patients hold inaccurate—and usually overly 
optimistic—perceptions of their prognosis.  Previous research has shown that advanced 
cancer patients overestimate their likelihood of cure and long-term survival, 
misunderstand treatment intent to be curative when it is palliative, and do not 
acknowledge the terminal nature of their illness.1,6-9    
 
Most of the previous research on prognostic understanding was carried out in solid 
tumor populations.1,6-9  There is comparatively little data for hematologic malignancies.  
A few small studies have found that patients undergoing hematopoietic stem cell 
transplant overestimate their prognosis.10-13  El-Jawahri et al. found that 77.6% of 
transplant recipients overestimated chance of cure compared to their oncologist’s 
assessment.  This was despite a reported desire for prognostic information: 88.9% of 
patients said it was “extremely” or “very” important to learn about their prognosis, and 
74.4% wanted “as much information as possible” about their prognosis.10  Grulke et al. 
reported that transplant recipients’ prognostic estimates correlated with their 
psychological symptom burden, but not with objective disease- or treatment-related 
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variables.11  More recently, El-Jawahri et al. conducted another study in older adults 
with acute myeloid leukemia (AML), finding that these patients overestimated both 
their likelihood of cure and the risk of treatment-related mortality.14  However, 
prognostic understanding in the acute leukemia population remains insufficiently 
studied. 
 
Acute leukemias differ from solid tumors in key ways that make researching patient and 
physician understanding of prognosis challenging.  First, there is a difference in 
curability: whereas advanced solid tumors are usually unambiguously incurable, in acute 
leukemia there is often a real possibility of cure that must be balanced against a high 
risk of complications.15  Second, there is a difference in illness trajectory: whereas solid 
tumors usually have a gradual onset and progress linearly, acute leukemias often 
present suddenly and follow an unpredictable course marked by intermittent periods of 
acute exacerbation and intensive treatments.16-18  A patient’s condition can deteriorate 
suddenly and dramatically due to infection or hemorrhage, contributing to uncertainty 
in prognostication and timing of goals of care discussions.17   
 
Why does prognostic understanding matter?  Evidence is accumulating that prognostic 
misperceptions can influence treatment preferences and ultimately patterns of care.  In 
a large cohort of patients with metastatic solid tumors, Weeks et al. demonstrated that 
overestimation of survival was associated with a preference for, and ultimately receipt 
of, more aggressive treatment.19  In the Coping with Cancer study, Enzinger et al. found 
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that patients who overestimated their survival were less likely to complete advance care 
planning such as do-not-resuscitate orders and living wills.1     
 
Little is known about the link between prognostic understanding and patterns of care in 
hematologic malignancies.  In a large national survey in which hematologic oncologists 
were asked to identify barriers to providing quality end-of-life care for patients with 
blood cancers, the top reported barrier was unrealistic patient expectations.20  This 
topic merits further investigation because hematologic malignancy patients have 
especially high rates of healthcare utilization and aggressive treatment at the end of life.  
Compared to their counterparts with solid tumors, patients with hematologic 
malignancies are more than twice as likely to die in the hospital and more likely to 
undergo hospitalization, ICU admission, and chemotherapy within 30 days of death.21,22  
They are less likely to receive palliative care or hospice services, and when they do 
enroll in hospice it is often just days before death; this is particularly true for patients 
with leukemia.23-25 
 
Here, we report results of an observational study examining prognostic understanding 
and end-of-life outcomes in acute leukemia.  Our study differs from previous work in the 
hematologic malignancy population in four key ways.  First, we include patients at all 
stages of the acute leukemia disease trajectory (including new diagnosis, remission, and 
relapsed/refractory disease).  Previous studies focused more narrowly on either newly 
diagnosed patients or those undergoing transplant.10-14,26  Recently, Kayastha et al. 
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examined the impact of relapse status on patient-reported outcomes such as quality of 
life and distress, but they did not assess prognostic understanding.27  Further research is 
needed to more completely capture how prognostic understanding varies at different 
stages of illness, for example after relapse. 
 
Second, we evaluate the various components of prognostic understanding in richer 
detail.  Experts in patient-physician communication have identified 5 distinct elements 
of prognostic understanding: current state of disease, life expectancy, curability, decline 
trajectory, and available treatment options.28  Our study recognizes this 
multidimensionality by asking not only about chance of cure but also about other 
elements that are less commonly studied, such as chance that treatment will reduce 
suffering.  Third, we compare patient perceptions of prognosis to both physician 
opinions and actual survival outcomes.  Finally, we assess healthcare utilization at the 
end of life to explore the link between prognostic perceptions and patterns of care.  
 
STATEMENT OF PURPOSE 
The purpose of this observational study was to assess how well patients with acute 
leukemia at Yale-New Haven Hospital understand their prognosis by comparing patients’ 





Aim 1: To describe patient and physician (treating hematologist) perceptions of 
prognosis and goals of care.  
Aim 2: To measure patient-physician concordance regarding prognosis and goals of 
care.  
Aim 3: To identify patient demographic and clinical factors associated with prognostic 
understanding. 
Aim 4: To compare perceptions of prognosis to actual survival outcomes.  
Aim 5: To assess healthcare utilization at the end of life. 
 
Hypothesis 
Our hypothesis was that patient-physician concordance regarding prognosis would be 




Patients eligible for this study were adults with acute leukemia (including acute myeloid 
leukemia and acute lymphoblastic leukemia) admitted to Smilow Cancer Hospital at 
Yale-New Haven, the clinical arm of the Yale Cancer Center.  Exclusion criteria included 
not speaking English, serious cognitive impairment, and inability to communicate 
verbally with researchers. 
 
Study design and procedures  
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This study was approved by the Yale Institutional Review Board.  We identified 
potentially eligible patients by screening the inpatient hematologic malignancy service 
census.  Consecutively eligible patients were invited to participate and provided written 
informed consent.  Enrollment occurred between August 2015 and November 2017.   
 
Enrolled patients completed a survey (Appendix 1) administered in-person by a 
researcher.  For newly diagnosed patients, we waited at least 1 week after the date of 
diagnosis to administer the survey in order to allow time for cytogenetic testing and 
discussions about prognosis with a hematologist.  Then, we asked each patient’s 
treating hematologist to complete a short survey (Appendix 2) assessing the individual 
patient’s prognosis and goals of care, using a subset of the items on the patient survey.  
We conducted an initial medical record review at the time of enrollment to abstract 
clinical factors.  Finally, in December 2018, after a minimum of 1 year of follow-up, we 
conducted another medical record review to assess survival outcomes and healthcare 
utilization at the end of life.  
 
Measures  
Perceptions of prognosis and goals of care.  Several items assessing prognostic 
perceptions were adapted from the Coping with Cancer study, a large, multisite, 




We asked patients whether they would want to be told their prognosis and elicited their 
preferences for involvement in treatment decision-making.  We also asked whether they 
recalled their physician discussing expected survival time, treatment response rates, or 
end-of-life preferences.   
 
We asked both patients and their physicians to complete the following 6 survey items, 
so that patient vs physician responses could be compared.  1) We asked participants to 
rate current health status as “relatively healthy,” “seriously ill,” or “terminally ill.”  2) We 
asked whether the goal of current treatment was “cure,” “extend life,” or “lessen 
suffering.”  3) Likelihood of cure, 4) likelihood of extending life, and 5) likelihood of 
lessening suffering were each rated on a 5-point scale (0-20%, 21-40%, 41-60%, 61-80%, 
and 81-100%).  6) Finally, we asked participants to estimate survival time, with options 
ranging from months to years. 
 
Demographic factors.  Patients reported age, sex, race, ethnicity, marital status, income, 
education, religion, and level of religiosity.  Health insurance type was obtained from 
medical records.  
 
Clinical factors.  Type of leukemia, relapse status, and transplant status were identified 
by medical record review.  Health-related quality of life was assessed using the 
Functional Assessment of Cancer Therapy—Leukemia (FACT-Leu) Version 4 
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instrument.30  We also assessed Eastern Cooperative Oncology Group (ECOG) 
performance status for all patients.31  
 
Survival outcomes and healthcare utilization at the end of life.  At the end of the follow-
up period, survival outcomes were ascertained from medical records.  Overall survival 
was measured from the time of enrollment to death or censoring.  For patients who had 
died, we also obtained information on place of death, hospice enrollment, receipt of 
palliative care consultation, hospitalization within 30 days of death, ICU admission 
within 30 days of death, receipt of chemotherapy or targeted therapy within 14 days of 
death, CPR or intubation within 30 days of death, and transfusion of red blood cells or 
platelets within 7 days of death.  We chose these particular outcomes because they 
have previously been identified as standard quality measures for end-of-life care in the 
hematologic malignancy population.20  
 
Statistical analysis 
For the purpose of sample size calculation, we chose a primary outcome of patient-
physician discordance regarding likelihood of cure.  We calculated a minimum sample 
size of 76 patients to have 80% power to detect a >1 point difference on the 5-point 
likelihood-of-cure scale, using a 5% significance level.  We posited that a >1 point 
difference was clinically relevant, as this was in line with how previous studies have 




We calculated descriptive statistics for baseline patient characteristics, including means 
or medians for continuous variables and frequencies for categorical variables.  For our 
analysis comparing patient vs physician perceptions, we used two methods.  First, we 
reported frequency distributions of patient vs physician responses and used chi-square 
or Fisher’s exact tests to determine whether these distributions differed significantly.  
Second, we quantified the level of concordance between patient and physician 
responses using Cohen’s kappa statistics.  Kappa statistics were interpreted using 
benchmark ranges described by Landis and Koch; kappa values < 0.20 indicate poor or 
slight concordance, and kappa values of 0.8 to 1.0 indicate almost perfect 
concordance.34  
 
We used logistic regression to explore demographic and clinical factors associated with 
patient-physician prognostic concordance.  For these analyses, prognostic concordance 
was defined as patient and physician rating the likelihood of cure within 1 point of each 
other on the 5-point likelihood-of-cure scale.   
 
Survival analysis was conducted using the Kaplan-Meier method and log-rank tests for 
significance.  Analyses were performed using SAS software (version 9.4; SAS Institute 
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We enrolled 105 of 137 eligible patients (76.6% participation rate).  We restricted our 
analysis to the 90 patient-physician pairs in which both parties completed a survey.  
Baseline patient characteristics are listed in Table 1.  In terms of demographics, patients 
were predominantly white (77/90, 85.6%) and Christian (73/90, 81.1%).  The median age 
was 59.5 years (range 22 to 86), and half the patients were female (45/90, 50.0%).  In 
terms of clinical factors, most patients (73/90, 81.1%) had a diagnosis of AML, with the 
remainder having ALL.  Patients at all stages of illness were represented: 41.1% were 
newly diagnosed, 31.1% were in remission, and 27.8% had relapsed or refractory 
disease. In addition, a third of patients (30/90, 33.3%) had either previously undergone 
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hematopoietic stem cell transplant or were admitted to undergo transplant at the time 
of enrollment.  
 
Table 1: Baseline patient characteristics (n = 90) 
 
Characteristic No. % 
Age: median (range), years 59.5 (22-86) 
Sex 
   Male 








   White 








   Hispanic or Latino 







Type of leukemia 
   AML 







Disease status at enrollment 
   New diagnosis 
   Remission 









Number of relapses 
   0 








   No HSCT 
   Current admission for HSCT 










   Private 
   Medicare 









Education (n = 88)  
   ≤ High school 
   Some college or trade school 









Income (n = 75)  
   < $19,999 
   $20,000 - 79,999 
   $80,000 -139,999 











Marital status  







   Never married 






   Christian 







ECOG PS (n = 87)  
   0 
   1 or 2 










Abbreviations: AML, acute myeloid leukemia; ALL, acute 
lymphoblastic leukemia; HSCT, hematopoietic stem cell 
transplant; PS, performance status 
 
 
Patient perceptions of goals of care discussions 
Most patients (71/85, 83.5%) wanted to be told their prognosis.  Most patients (77/90, 
85.6%) also wanted to be involved in treatment decision-making, although a minority 
(13/90, 14.4%) preferred to leave all treatment decisions up to their physicians.  When 
asked to reflect on past conversations with their hematologist, only 56.8% (50/88) of 
patients recalled discussing chance of response to treatment, 28.1% (25/89) recalled 
discussing expected survival time, and 21.8% (19/87) recalled discussing end-of-life 
preferences.  
 
Patient-physician comparisons   
Patients were more optimistic than their physicians in assessing several different 
components of prognosis.  When asked to describe their current health status at the 
time of enrollment, only 9.0% (8/89) of patients responded “terminally ill,” compared to 




     
Figure 1. Patient vs physician perceptions of current health status.   
Abbreviation: MDs, physicians. 
 
 
When asked to select the primary goal of their current treatment, most patients (74/90, 
82.2%) and physicians (71/90, 78.9%) shared a goal of cure (Figure 2).  However, they 
differed significantly in their perceptions of the likelihood of cure.  The majority of 
patients (45/88, 51.1%) thought their chance of cure was > 80%, compared to only a 
small minority (3/90, 3.3%) of physicians (p < 0.001; Figure 3).  Table 2 shows a cross-
tabulation of paired patient-physician responses estimating chance of cure, illustrating 
how few pairs gave matching responses.  Kappa statistics confirmed that patient-




Figure 2. Patient vs physician perceptions of primary goal of care.    






Figure 3. Patient vs physician perceptions of the likelihood of cure.  Patients at all stages of 
illness (relapsed and non-relapsed) are included.  
 
 
Table 2: Patient-physician concordance regarding chance of cure (n = 88 pairs)A 
 Physician response 
Patient response 0-20% 21-40% 41-60% 61-80% 81-100% Total 
0-20% 5 2 0 1 0 8 
21-40% 2 1 1 1 0 5 
41-60% 5 2 2 1 0 10 
61-80% 9 3 4 4 0 20 
81-100% 8 13 15 6 3 45 
Total 29 21 22 13 3 88 
κ coefficient (95% CI) 0.05 (-0.02 to 0.13) 
 
A This table shows a cross-tabulation of paired patient-physician responses estimating 
chance of cure.  
 
 
Patients estimated chance of cure more optimistically than their physicians at all stages 
of illness.  This became apparent when patients were stratified by relapse status (Table 
3).  In the non-relapsed group, 57.9% (33/57) of patients vs only 5.2% (3/58) of their 
physicians reported a > 80% chance of cure (p < 0.001).  In the relapsed group, 38.7% 
p < 0.001 
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(12/31) of patients vs 0.0% (0/32) of their physicians reported a >80% chance of cure (p 
< 0.001). 
 
Table 3: Patient vs physician perceptions of chance of cure, stratified by relapse status 
 Non-relapsed (n = 58) 
Relapsed 















21-40 3.5 22.4 9.7 25.0 
41-60 12.3 32.8 9.7 12.5 
61-80 21.1 20.7 25.8 3.1 
81-100 57.9 5.2 38.7 0.0 
 
 
Patients were also more optimistic than their physicians about the likelihood that 
treatment would extend their life (Figure 4) and the likelihood that treatment would 
lessen their suffering (Figure 5).  Only 41.1% (37/90) of surveyed patients were willing to 
estimate how much longer they had to live; the rest responded “don’t know,” “in God’s 
hands/up to fate,” or left the question blank.  Among those willing to provide an 
estimate, 75.7% (28/37) of patients vs 28.4% (21/74) of physicians estimated a survival 
time of > 5 years (p < 0.001; Figure 6).  Patient-physician concordance was poor for 
chance of extending life (κ = 0.08; 95% CI, -0.04 to 0.20), chance of lessening suffering (κ 














Figure 6.  Patient vs physician estimates of survival time.  
 
 
p < 0.001 
p < 0.001 




Exploratory analyses of associations between prognostic concordance and other 
covariates 
We conducted an exploratory analysis with the goal of identifying demographic and 
clinical factors associated with patient-physician prognostic concordance.  However, no 
associations emerged as significant in our bivariate or multivariable models.  Specifically, 
there were no associations between prognostic concordance and age, sex, race, 
insurance type, education, religion, ECOG performance status, or relapse status.  
Prognostic concordance was also not significantly associated with health-related quality 
of life as measured by FACT-Leu.  
 
Comparison of estimated vs actual survival time 
By the end of the follow-up period, 53.3% (48/90) of patients in the cohort had died.  
The median overall survival of the entire cohort was 18 months (95% CI, 13 to 30 
months).  Figure 7 shows Kaplan-Meier survival plots stratified by relapse status; non-
relapsed patients lived significantly longer than relapsed patients (median survival, 23 
months vs 7 months, p = 0.002).  
 
For participants who had been willing to estimate survival time on the baseline survey (n 
= 37 patients and n = 74 physicians), we compared estimated vs actual survival (Figure 
8).  Only 8.1% (3/37) of patients and 14.9% (11/74) of physicians provided an accurate 
estimate (actual survival was within the time range estimated).  Both patients and 
physicians were more likely to overestimate than underestimate survival, but patients 
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were especially optimistic: 54.1% (20/37) of patients vs 33.8% (25/74) of physicians 
overestimated, and 5.4% (2/37) of patients vs 12.2% (9/74) of physicians 
underestimated (p < 0.001). 
 
 
Figure 7: Overall survival stratified by relapse status at the time of enrollment.  Shaded areas 






Figure 8: Accuracy of patients’ and physicians’ survival time estimates, as compared to actual 
survival.  “Longer follow-up time needed to evaluate accuracy” means that the patient was still 
alive at the end of the follow-up period but had not yet attained the estimated survival time.  
 
 
Healthcare utilization at the end of life 
Table 4 shows healthcare utilization at the end of life for the 48 patients who died 
during follow-up.  Half of these patients (24/48, 50.0%) died in the hospital as opposed 
to at home or in hospice.  Although 47.9% (23/48) of those who died received hospice 
services, transition to hospice usually only occurred when death was imminent: only 
10.4% (5/48) enrolled in hospice more than 7 days before dying.  Within 30 days of 
death, 93.8% (45/48) of patients were hospitalized, 54.2% (26/48) were admitted to the 
ICU, 33.3% (16/48) were intubated, and 10.4% (5/48) received CPR.  Within 14 days of 
death, 41.7% (20/48) of patients received chemotherapy or targeted therapy.  Within 7 
days of death, 66.7% (32/48) of patients received a red blood cell or platelet transfusion.  








Table 4: Healthcare utilization at the end of life (n = 48 patients) 
 
Characteristic No. of patients % 
Place of death 
   Hospital 
   Hospice (home services or inpatient facility)    









Hospice enrollment  
   > 7 days before death 







Hospitalization within 30 days of death 45 93.8 
ICU admission within 30 days of death 26 54.2 
CPR within 30 days of death 4 8.3 
Intubation within 30 days of death 16 33.3 
Chemotherapy or targeted therapy within 14 days of death 20 41.7 
Transfusion within 7 days of death 32 66.7 
Received palliative care consult 31 64.6% 
 






Several key findings emerged from this study of prognostic understanding and end-of-
life outcomes in the acute leukemia population.  First, more patients wanted to know 
their prognosis than recalled discussing it with their hematologist, indicating a gap 
between patients’ desire for and receipt of prognostic information.  Second, we found 
substantial discrepancies between patient and hematologist perceptions of prognosis.  
Patients tended to be more optimistic: they were less likely to label themselves 
terminally ill, more likely to perceive a high chance of cure, and more likely to estimate a 
survival time of > 5 years.  Third, both patients and physicians overestimated survival, 
with patients being especially optimistic.  Fourth, healthcare utilization at the end of life 




Our finding of a large patient-physician discrepancy in perceived chance of cure is in line 
with other recent studies in the hematologic malignancy population.10,14  In our study’s 
acute leukemia population, 51.1% of patients vs 3.3% of physicians thought their chance 
of cure was > 80%; similarly, in a recent study of older adults with AML, El-Jawahri et al. 
reported that 52% of patients vs 0% of physicians thought their chance of cure was > 
75%.14  
 
One unique aspect of our study was that we assessed multiple dimensions of prognostic 
understanding, asking not only about chance of cure but also about current health 
status, goals of care, estimated survival time, and likelihood that treatment would 
extend life or lessen suffering.  Perceptions of anticipated suffering have been 
particularly overlooked in previous research.  In our study, patients were more likely 
than their physicians to think that the treatment they were receiving would reduce their 
suffering.  This discrepancy suggests that patients may be minimizing the risk of side 
effects and overestimating how treatment would alleviate their symptom burden.  In 
fact, physical and psychosocial symptom burdens often increase during active 
treatment.27,35  Misperceptions about anticipated suffering are especially important to 
recognize in patients for whom goals of care have shifted from extending life toward 
preserving quality of life.   
 
In our study, the gap between patient and physician understanding was most striking in 
the relapsed group.  Over a third of relapsed patients vs none of their physicians 
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thought chance of cure was > 80%.  Inaccurate prognostic perceptions likely have a 
greater impact on treatment decisions in the relapsed population—especially in 
relapsed patients who are also older and frail.  Young, relatively fit patients with newly 
diagnosed leukemia would likely choose the same treatment—intensive induction 
chemotherapy—whether they inaccurately believed their chance of cure to be > 80% or 
accurately understood it to be 30-40%.  On the other hand, for older, medically frail 
patients with relapsed disease deciding whether to pursue further lines of cure-directed 
therapy, the difference between inaccurately believing chance of cure to be > 80% and 
accurately understanding it to be < 10% could be quite consequential.  Unrealistic 
expectations may predispose vulnerable patients toward overly aggressive and perhaps 
futile treatment.  Thus, the high rate of prognostic overestimation among relapsed 
patients is particularly concerning.   
 
Our findings raise the question of whether oncologists in clinical practice should be 
aiming for perfect patient-physician agreement on prognosis.  Is patients’ relative 
optimism always problematic?  Optimism can be part of a constructive coping strategy, 
and may help patients persevere through prolonged, socially isolating hospitalizations 
and intensive, high-toxicity treatments.36  Oncologists often worry that disclosing a poor 
prognosis will take away hope or otherwise cause psychological harm.20,37  We did not 
find any significant association between prognostic understanding and quality of life, 




The existing literature on this topic has yielded mixed results.  In a study on the 
psychological impact of acute leukemia, Gheihman et al. found that while depression 
was common and related to physical symptom burden, hopelessness was less common 
and associated with older age and lower self-esteem.  Perceived poor communication 
with healthcare providers was not independently associated with hopelessness.16  In the 
Coping with Cancer study, prognostic disclosures were not associated with emotional 
distress or harm to the patient-physician relationship.1  However, in another study of 
patients with advanced gastrointestinal cancer, accurate prognostic understanding was 
associated with worse quality of life and anxiety.38  Finally, in the hematologic 
malignancy population, El-Jawahri and colleagues reported that more accurate 
prognostic understanding was associated with worse quality of life and increased 
depression.10,14  Given the lack of consensus, a cautious approach to prognostic 
disclosure is warranted.  In their conversations with patients, oncologists must balance 
maintaining hope with the need to set realistic expectations to enable informed 
decision-making. 
 
The intensity of healthcare utilization at the end of life in our cohort matched or 
exceeded that found in previous studies in the hematologic malignancy 
population.22,24,25  In our cohort, within the last month of life almost all patients were 
hospitalized, over half were admitted to the ICU, and many received chemotherapy.  
While we observed a relatively high rate of hospice utilization (47.9%), enrollment was 
usually late, occurring just days before death.  Several factors may contribute to this 
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pattern.  On the one hand, it may reflect a sudden deterioration in clinical status and 
transition to end-of-life care.  Alternatively, it may point toward barriers to timely 
hospice enrollment such as a lack of blood product transfusion services.  In a study of 
Medicare beneficiaries with leukemia, transfusion dependence was associated with 
higher rates of hospice utilization but shorter lengths of stay.39  Indeed, in our cohort 
the majority of patients (66.7%) received a transfusion within a week of death; perhaps 
some deferred hospice enrollment because they would be unable to receive supportive 
transfusions.  This highlights the need for hospice services that allow transfusions as a 
component of comfort care.  
 
Interestingly, in our cohort we also observed a higher rate of utilization of palliative care 
services compared to previous reports.  In our sample, the majority (64.6%) of patients 
who died received a palliative care consult, compared to only 16.2% of a cohort of older 
adults with AML and 33% of patients in a heterogeneous cohort of hematologic 
malignancy patients, both at academic institutions.22,24  These variable rates may reflect 
institution-level differences in patterns of palliative care referral.    
 
Our study has several limitations.  First, the cross-sectional design of our survey did not 
allow for tracking changes in prognostic understanding over time.  A longitudinal study 
with surveys at different time points would be better suited for identifying clinical 
events along the disease trajectory that trigger changes in understanding.  Second, our 
small sample size consisting of predominantly white patients limited our ability to detect 
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associations between demographic and clinical variables and prognostic understanding 
in our exploratory analyses.  Previous studies in solid tumor populations have found that 
patients who are nonwhite, older, or non-native English speakers are more likely to 
report a prognosis or treatment intent that is discordant from their physician’s.7,32  
Third, we did not assess whether patients knew that their hematologist’s opinion 
differed from their own; in other words, we did not distinguish between known and 
unknown discordance.  Gramling et al. found that unknown discordance was more 
common in the advanced cancer population and posited that it is a marker of poor 
patient-provider communication.32  Fourth, in our analysis of healthcare utilization, we 
did not distinguish between chemotherapy given with curative vs palliative intent, which 
limited our ability to assess the appropriateness of high rates of chemotherapy 
administration near death.   
 
Finally, this study did not directly evaluate patient-physician communication.  Thus, the 
actual prognostic discussion remains a “black box,” and we are not able to determine 
the exact locus of the discrepancy in patient-physician perceptions.  Are physicians not 
disclosing the prognosis, or are patients simply not hearing it, perhaps because they are 
too overwhelmed to listen?  Future work will include audio recordings of prognostic 
discussions to crack open this “black box.” 
 
In summary, this observational study of prognostic understanding in the acute leukemia 
population revealed that most patients strikingly overestimate their prognosis 
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compared to their hematologist's assessment and to actual end-of-life outcomes.  This 
study went beyond previous work by assessing more dimensions of prognostic 
understanding and comparing patients at different stages of illness.  Our findings are 
significant because, while optimism can help with coping, there is also a risk of 
unrealistic expectations influencing treatment decisions, especially after relapse.  Future 
work will focus on two areas: 1) examining actual patient-physician prognostic 
conversations and 2) further exploring associations between prognostic understanding 
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Appendix 1: Patient Survey 
STUDY ID #: _________ 




Please circle your answers.  
 
A: THE BRIEF ILLNESS PERCEPTION QUESTIONNAIRE (B-IPQ) 
For the following questions, please circle the number that best corresponds to your views now. 
1. How much does 




No effect at all 
1 2 3 4 5 6 7 8 9 10 
Severely affects 
my life 
2. How long do you 




A very short 
time 
1 2 3 4 5 6 7 8 9 10 
For the rest of 
my life 
3. How much control 
do you feel you 





control       




4. How much do you 
think your 




Not at all                              
1 2 3 4 5 6 7 8 9 10     
Extremely 
helpful 







at all            
1 2 3 4 5 6 7 8 9 10     
Many severe 
symptoms 
6. How concerned are 




Not at all 
concerned          
1 2 3 4 5 6 7 8 9 10     
Extremely 
concerned 
7. How well do you 







1 2 3 4 5 6 7 8 9 10     
Understand 
very clearly 
8. How much does 
your illness affect 
you emotionally? 
(e.g., does it make 
0 
Not at all 
affected             
emotionally 











B: CONTROL PREFERENCES SCALE (CPS) 
1. In terms of making decisions about your health care with your doctor, which ONE of the 
following best describes how you would like to make these decisions?  
(1) Make the final selection about which treatment I will receive 
(2) Make the final selection after seriously considering my doctor's opinion  
(3) Have my doctor and I share responsibility for deciding what treatment is best  
(4) Have my doctor make the final decision but consider my opinion  
(5) Leave all decisions regarding treatment to my doctor 
 
C: UNDERSTANDING OF PROGNOSIS 
1. How would you describe your current health status? 
(1) Relatively healthy 
(2) Seriously ill but not terminally ill 
(3) Seriously and terminally ill 
 
2. Did your cancer doctor discuss how long you may have to live? 
(1) Yes   
(2) No 
 





4. Based on your understanding about what your doctors have told you about your cancer, 
your health in general, and the treatments you are receiving, how long do you think you 
have to live? 
(1) Up to 3 months 
(2) 3 to 6 months 
(3) 6 to 12 months 
(4) 1-2 years 
(5) 2-5 years 
(6) At least 5 years 
(7) In God’s hands/Up to fate 
(8) Don’t know 
 
5. What is the basis of this estimate of how long you have to live? 
(1) My cancer doctor told me 
(2) A palliative care specialist told me 
(3) Other clinic staff told me 
(4) My personal belief, having to do with religion 
(5) My personal belief, not having to do with religion 






D: PERCEPTION OF GOALS OF CARE AND TREATMENT PREFERENCES 
1. Did your cancer doctor talk to you about your goals of care?  A goals of care 
conversation includes discussions about the likely outcome of your illness, possible 





2. What is the primary goal of your current medical treatment? 
(1) To cure my cancer 
(2) To extend my life as long as possible without cure 
(3) To lessen suffering as much as possible 
 
3. How likely do you think you are to be cured of cancer? 
(1) Very likely  
(2) Likely  
(3) Unlikely  
(4) Very unlikely  
 
4. If you had to estimate your chance of being cured of cancer, what would it be? 
(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
(6) 81% to 100% 
 
5. How likely do think it is that your current treatment will extend your life?  
(1) Very likely  
(2) Likely  
(3) Unlikely  
(4) Very unlikely  
 
6. If you had to estimate the chance that your current treatment will extend your life, what 
would it be? 
(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
(6) 81% to 100% 
 
7. How likely do you think it is that your current treatment will lessen your suffering? 
(1) Very likely  
(2) Likely  
33 
 
(3) Unlikely  
(4) Very unlikely  
 
8. If you had to estimate the chance that your current treatment will lessen your suffering, 
what would it be? 
(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
(6) 81% to 100% 
 
9. Did your cancer doctor discuss specific numbers about your chance of responding to 




10. Did your cancer doctor talk to you about medications or treatments that could help with 
the side effects of your cancer treatments or help with the side effects of the cancer 
itself? 
(1) Yes  
(2) No 
 




12. Overall, do you agree that the treatments you’ve gotten for your cancer match your 
preferences? 
(1) Strongly Disagree 
(2) Disagree 
(3) Neither agree nor disagree 
(4) Agree 
(5) Strongly agree 
 
13. What is more important to you: treatment that focuses on quality of life or treatment 
that focuses on lengthening life? 
(1) Focus on quality of life 
(2) Focus on lengthening life 
 




(3) Don’t know 
 
15. Do you think your doctor would offer you treatment that would not help you just 






16. Do you think your doctor would offer you treatment that would not help you but would 
help others with the information its effect on you would provide? 
(1) Yes  
(2) No 
 
17. Have you and your doctor discussed any particular wishes you have about the care you 




18. Do you have a signed Living Will or Durable Power of Attorney for health care, both, or 
neither? 
(1) Yes, Living Will 
(2) Yes, Durable Power of Attorney 
(3) Yes, both 
(4) Neither 
(5) Don’t know 
 
19. Have you completed a Do Not Resuscitate (DNR) order? 
(1) Yes 
(2) No 
(3) Don’t know 
 
20. Do you think it would be a bad thing for a person to die in the ICU versus elsewhere (e.g. 




21. Would you want the doctors here to do everything possible to keep you alive even if you 





E: RELIGIOUSNESS  












(10) Other (SPECIFY): ________________________________ 
 
2. How religious/spiritual do you consider yourself to be? 
(1) Not at all 
(2) A little 
(3) Somewhat 
(4) Very 
(5) I don’t know 
 
3. To what extent do your religious beliefs or activities help you cope with or handle your 
illness?  
(1) Not at all 
(2) To a small extent 
(3) To a moderate extent 
(4) To a large extent 
(5) It is the most important thing that keeps me going 




1. How old are you?  _____ years old 
 
2. What is your gender? 
(1) Male  
(2) Female 
(3) Other (SPECIFY): _________________________________________________ 
 
3. Are you now married, living with a partner in a marriage-like relationship, widowed, 
divorced, separated, or never married? 
(1) Married 
(2) Living with partner 
(3) Widowed  
(4) Divorced 
(5) Separated 
(6) Never married 
 




5. What type of health insurance coverage do you currently have? 
(1) Private health insurance or HMO  
(2) Medicare  
(3) Medicaid  
(4) Veteran’s administration (VA) health care   
(5) Other government health plan   
(6) Other non-government health plan  




6. What is the highest grade of school you have completed? 
(1) Never attended/Kindergarten only 
(2) Less than Junior High school (grades 1-8) 
(3) Less than High School (grades 8-11) 
(4) High School graduate or GED 
(5) Some college, no degree 
(6) Trade/Vocational school 
(7) College degree 
(8) Graduate School 
 
7. How often do you need to have someone help you when you read instructions, 




(4) Often  
  




9. What is your race? 
a. White  
b. Black or African American 
c. Asian 
d. American Indian/Alaskan Native 
e. Native Hawaiian/Pacific Islander 
f. More than one race (SPECIFY): ___________________________________ 
g. Other (SPECIFY): _________________________________________ 
 
10. Which of the following categories best describes the total amount of money that came 
into your household last year before taxes?  
a. $ 0-19,999 
b. $ 20,000-39,999 
c. $ 40,000-59,999 
d. $ 60,000-79,999 
e. $ 80,000-99,999 
f. $ 100,000-119,000 
g. $ 120,000-139,000 
h. $ 140,000 and over 









Appendix 2: Physician Survey 
 
Study ID #: _________              Physician Assessment of Prognosis and Primary Goal of Care 
 
Please circle your answers.  
 
1. How would you describe this patient’s current health status? 
(1) Relatively healthy 
(2) Seriously ill but not terminally ill 
(3) Seriously and terminally ill 
 
2. How long do you think this patient has to live? 
(1) Up to 3 months 
(2) 3 to 6 months 
(3) 6 to 12 months 
(4) 1-2 years 
(5) 2-5 years 
(6) At least 5 years 
(7) In God’s hands/Up to fate 
(8) Don’t know 
 
3. What is the primary goal of this patient’s current medical treatment? 
(1) To cure the cancer 
(2) To extend life as long as possible without cure 
(3) To lessen suffering as much as possible 
 
4. How likely do you think this patient is to be cured of cancer? 
(1) Very likely  
(2) Likely  
(3) Unlikely  
(4) Very unlikely  
 
5. Please estimate the chance that this patient will be cured of cancer.  
(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
(6) 81% to 100% 
 
6. How likely do think it is that this patient’s current treatment will extend his or her life?  
(1) Very likely  
(2) Likely  
(3) Unlikely  
(4) Very unlikely  
 




(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
(6) 81% to 100%  
 
8. How likely do you think it is that this patient’s current treatment will lessen his or her 
suffering? 
(1) Very likely  
(2) Likely  
(3) Unlikely  
(4) Very unlikely  
 
9. Please estimate the chance that this patient’s current treatment will lessen his or her 
suffering.  
(1) 0%  
(2) 1% to 20% 
(3) 21% to 40% 
(4) 41% to 60% 
(5) 61% to 80% 
 
